Literature DB >> 17021909

[Chronic critical ischemia of the lower leg: pretherapeutic imaging and methods for revascularization].

M Treitl1, V Ruppert, A K Mayer, C Degenhart, M Reiser, J Rieger.   

Abstract

Each year 1-2% of patients with peripheral arterial occlusive disease (pAOD) develop critical limb ischemia (CLI), characterized by rest pain and peripheral ulcer or gangrene. This aggravation of the disease is accompanied by an increase of the 1-year mortality rate up to 25% and a similarly increased frequency of major amputation. We can choose between conservative, endovascular, and surgical procedures for an adequate therapy of the underlying vascular stenoses or occlusions. Yet, clear therapeutic recommendations only exist for suprapopliteal lesions. However, in a number of cases, especially in diabetics, target lesions have an infrapopliteal location. Since endovascular procedures have undergone significant improvement in the last few years, the following review discusses methods for infrapopliteal revascularization taking into consideration the newest publications on this topic.

Entities:  

Mesh:

Year:  2006        PMID: 17021909     DOI: 10.1007/s00117-006-1423-2

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  74 in total

1.  Subintimal angioplasty of tibial vessel occlusions in the treatment of critical limb ischaemia: mid-term results.

Authors:  H Vraux; F Hammer; R Verhelst; P Goffette; B Vandeleene
Journal:  Eur J Vasc Endovasc Surg       Date:  2000-11       Impact factor: 7.069

Review 2.  Epidemiology and pathophysiology of lower extremity peripheral arterial disease.

Authors:  Lawrence A Garcia
Journal:  J Endovasc Ther       Date:  2006-02       Impact factor: 3.487

Review 3.  Rehabilitation of the older lower limb amputee: a brief review.

Authors:  T M Cutson; D R Bongiorni
Journal:  J Am Geriatr Soc       Date:  1996-11       Impact factor: 5.562

Review 4.  Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review.

Authors:  J I Weitz; J Byrne; G P Clagett; M E Farkouh; J M Porter; D L Sackett; D E Strandness; L M Taylor
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

5.  PTA versus carbofilm-coated stents in infrapopliteal arteries: pilot study.

Authors:  T Rand; A Basile; M Cejna; D Fleischmann; M Funovics; M Gschwendtner; M Haumer; I Von Katzler; J Kettenbach; F Lomoschitz; C Luft; E Minar; B Schneider; M Schoder; J Lammer
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Jan-Feb       Impact factor: 2.740

6.  Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices.

Authors:  G Dangas; R Mehran; S Kokolis; D Feldman; L F Satler; A D Pichard; K M Kent; A J Lansky; G W Stone; M B Leon
Journal:  J Am Coll Cardiol       Date:  2001-09       Impact factor: 24.094

7.  Infrainguinal revascularization because of claudication: total long-term outcome of endovascular and surgical treatment.

Authors:  Tiia S Jämsén; Hannu I Manninen; Harri E Tulla; Pekka A Jaakkola; Pekka J Matsi
Journal:  J Vasc Surg       Date:  2003-04       Impact factor: 4.268

8.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

9.  Safety of gadolinium contrast angiography in patients with chronic renal insufficiency.

Authors:  Albert D Sam; Mark D Morasch; Jeremy Collins; Gina Song; Richard Chen; F Scott Pereles
Journal:  J Vasc Surg       Date:  2003-08       Impact factor: 4.268

10.  Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.

Authors:  Ryuichi Morishita; Motokuni Aoki; Naotaka Hashiya; Hirofumi Makino; Keita Yamasaki; Junya Azuma; Yoshiki Sawa; Hikaru Matsuda; Yasufumi Kaneda; Toshio Ogihara
Journal:  Hypertension       Date:  2004-07-06       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.